Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 4
2019 6
2020 5
2021 3
2022 8
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. Cappellini MD, et al. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. N Engl J Med. 2020. PMID: 32212518 Clinical Trial.
Management of TKI-resistant chronic phase CML.
Hughes TP, Shanmuganathan N. Hughes TP, et al. Among authors: shanmuganathan n. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):129-137. doi: 10.1182/hematology.2022000328. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485117 Free PMC article. Review.
Early Management of CML.
Shanmuganathan N, Hughes TP. Shanmuganathan N, et al. Curr Hematol Malig Rep. 2019 Dec;14(6):480-491. doi: 10.1007/s11899-019-00550-8. Curr Hematol Malig Rep. 2019. PMID: 31701368 Review.
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. Mauro MJ, et al. Among authors: shanmuganathan n. Leukemia. 2023 May;37(5):1048-1059. doi: 10.1038/s41375-023-01860-w. Epub 2023 Mar 22. Leukemia. 2023. PMID: 36949155 Free PMC article. Clinical Trial.
Accelerated-phase CML: de novo and transformed.
Shanmuganathan N, Hughes TP. Shanmuganathan N, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):459-468. doi: 10.1182/hematology.2023000446. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066863
34 results